Smith & Nephew posts sharp rise in profit and cash flow

Smith & Nephew delivered a strong finish to 2025 with Q4 revenue of $1.7bn (+8.3%, +6.2% underlying) and full-year revenue of $6.2bn (+6.1%, +5.3% underlying). Operating profit rose 20.7% to $794m and trading profit increased 15.5% to $1.2bn as trading margins expanded to 19.7% (from 18.1%); free cash flow jumped 52.5% to $840m, enabling a 4.3% higher full-year dividend (39.1¢) and completion of a $500m buyback. Management guides 2026 underlying revenue growth of ~6%, organic trading profit growth of ~8% and free cash flow around $800m, and notes the recent Integrity Orthopaedics acquisition is marginally dilutive this year but expected to be accretive by 2028 with trading profit now forecast near $1.3bn.

Analysis

Market structure: Smith & Nephew (SNN) is now a clearer winner among mid-cap ortho-device names after a three-year turnaround — Q4 underlying revenue +6.2% and trading margin 19.7% provide pricing leverage versus peers. Winners include SNN suppliers of high-margin implants and M&A-minded PE/strategic buyers; losers could be lower-efficiency competitors (Zimmer Biomet ZBH, Stryker SYK) if they cannot replicate margin gains. The completed $500m buyback and $840m FCF (up 52%) tighten free-float and should compress equity volatility and corporate credit spreads in the near term.

Risk assessment: Tail risks include acquisition/integration failure (Integrity Orthopaedics dilutive in 2026), regulatory setbacks on devices, or a macro-driven elective surgery downturn (>5% drop in procedure volumes would materially hit revenue). Timeframes: expect immediate positive re-rating (days-weeks), guidance-driven performance over 6–12 months, and strategy execution risk over 24+ months. Hidden dependencies: shares still sensitive to USD/GBP moves and reimbursement policy shifts in the US; FX moves of ±5% would swing reported revenue materially.

Trade implications: Direct play — size a 2–3% long SNN position targeting 12–18% upside over 12 months, stop-loss 10%, given guidance of ~6% revenue growth and ~$800m FCF for 2026. Pair trade — long SNN vs short ZBH or SYK 1:1 notional for 6–12 months to isolate execution; expect relative outperformance if margins stay >19%. Options — buy a 6–9 month call spread (ATM to +20% strike) to cap premium; exit on 12% absolute gain or final H1 2026 trading profit beat.

Contrarian angles: Consensus may underweight sustainability of margin expansion — buybacks + one-off cost saves can mean reversion once restructuring benefits exhaust, especially with acquisitions that are initially dilutive. Reaction could be underdone if RISE strategy delivers incremental organic growth >200–300bps vs peers, but overdone if Integrity integration drags $50–100m of EBITDA in 2026. Watch operating margin trajectory and FCF delta vs guidance as the decisive arbiter over next 4 quarters.

Key Decisions for Investors

• Establish a 2–3% long position in SNN within 1–3 weeks, target 12–18% upside over 12 months; set a hard stop-loss at 10% to limit downside if margins revert or M&A disappoints.
• Implement a relative-value pair trade: long SNN / short ZBH or SYK 1:1 notional for a 6–12 month horizon to hedge macro risk and capture expected margin outperformance; rebalance if spread narrows by >50% of initial.
• Buy a 6–9 month SNN call spread (ATM to ~+20% strike) sized to equal 1–1.5% portfolio risk to participate in upside while capping premium; close on 12% absolute share gain or after H1 2026 trading profit release.
• If SNN misses FCF by >$100m vs guidance or integration of Integrity shows >6 months delay, reduce net exposure to zero within 5 trading days; conversely increase exposure by 50% if trading profit guidance is raised and FCF outturn beats by >$100m.